Legal Representation
Attorney
Elizabeth Lee
USPTO Deadlines
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 19, 2022 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Dec 19, 2022 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Dec 19, 2022 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Jun 7, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jun 7, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 7, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 12, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 6, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 8, 2021 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Nov 8, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 8, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 12, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 12, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Sep 28, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 28, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 30, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 2, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 2, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 13, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 29, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 29, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 29, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 29, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 29, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 9, 2020 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jul 9, 2020 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Jul 9, 2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Jun 13, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 13, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 11, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 4, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 4, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 4, 2019 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 4, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 7, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 7, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 7, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 8, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 8, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 8, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 27, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 21, 2019 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 8, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 19, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Biopharmaceutical preparations for medical purposes, namely, monoclonal antibodies for use in vaccines, therapy, diagnosis and research, biotechnological origin antibodies for use in therapy, diagnosis and research, antibody fragments for use in therapy, diagnosis and research, fused antibody fragments for use in therapy, diagnosis and research, conjugated antibodies for use in therapy, diagnosis and research, engineered antibodies for use in therapy, diagnosis and research, vaccines and natural biomaterials for augmentation of bone and tissue, biotechnological scaffolds for cell therapy products and controlled released drugs, synthetic protein scaffolds, engineered antibodies scaffolds, non-antibody binding proteins for pharmaceutical and industrial applications, proteins for pharmaceuticals and industrial applications
First Use Anywhere:
Dec 31, 2006
First Use in Commerce:
Feb 28, 2019
Additional Information
Design Mark
The mark consists of the wording "3P" with "3" in pink and the "P" in fuchsia. To the left is a fuchsia curved line design forming a "3" superimposed over the letter "P", with the word "BIOPHARMACEUTICALS" in fuchsia in vertical form to the left of the design.
Color Claim
The color(s) fuchsia and pink is/are claimed as a feature of the mark.
Pseudo Mark
THREE P BIO PHARMACEUTICALS
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"BIOPHARMACEUTICALS"